Deciphera Pharmaceuticals (NASDAQ:DCPH) stock is rising higher on Monday after signing a $2.4 billion acquisition agreement with ONO Pharmaceutical (OTCMKTS:OPHLY). This deal has ONO acquiring ...
On Monday, Japanese pharma company ONO Pharmaceutical agreed to acquire Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) for $25.60 per share in cash, for a total equity value of $2.4 billion. Deciphera ...
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Deciphera Pharmaceuticals, Inc. (DCPH) one of those stocks right now? By taking a ...
Deciphera Pharmaceuticals’ shares surged 74.3% in the past month after the cancer-focused, commercial-stage biopharmaceutical company announced entering into a definitive merger agreement with ONO ...
It has been about a month since the last earnings report for Deciphera Pharmaceuticals, Inc. . Shares have lost about 9.7% in that time frame, underperforming the S&P 500. Will the recent negative ...
Sometimes, a big sell off can also be a big opportunity. But that’s not the case here with biotech play Deciphera Pharmaceuticals (NASDAQ:DCPH). On Nov. 5, DCPH stock took a sudden plunge of more than ...
Deciphera Pharmaceuticals, Inc. DCPH currently looks like a good stock from the biotech sector to invest in. Though smaller biotech companies are riskier as their product pipelines are several years ...
Deciphera Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results